UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 444

Sortiert nach

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

The American journal of medicine, 2011, Vol.124 (1), p.S3-S18

Nauck, Michael A., MD, PhD

2011

Link zum Volltext

Verfügbarkeit prüfen

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

Molecular metabolism (Germany), 2021-04, Vol.46, p.101102-101102, Article 101102

2021

Link zum Volltext

Verfügbarkeit prüfen

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

The lancet. Diabetes & endocrinology, 2016-06, Vol.4 (6), p.525-536

2016

Link zum Volltext

Verfügbarkeit prüfen

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

The Lancet (British edition), 2006-11, Vol.368 (9548), p.1696-1705

2006

Link zum Volltext

Verfügbarkeit prüfen

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Cardiovascular diabetology, 2022-09, Vol.21 (1), p.1-169, Article 169

2022

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

The New England journal of medicine, 2016-07, Vol.375 (4), p.311-322

2016

Link zum Volltext

Verfügbarkeit prüfen

Do GLP-1-Based Therapies Increase Cancer Risk?

Diabetes care, 2013-08, Vol.36 (8), p.S245-S252

2013

Link zum Volltext

Verfügbarkeit prüfen

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Diabetes care, 2021-08, Vol.44 (10), p.2438-2444

2021

Link zum Volltext

Verfügbarkeit prüfen

GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family

Diabetes (New York, N.Y.), 2019-05, Vol.68 (5), p.897-900

2019

Link zum Volltext

Verfügbarkeit prüfen

Long COVID - metabolic risk factors and novel therapeutic management

Nature reviews. Endocrinology, 2021-07, Vol.17 (7), p.379-380

2021

Link zum Volltext

Verfügbarkeit prüfen

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.699-704

2020

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

Frontiers in endocrinology (Lausanne), 2021-03, Vol.12, p.645566-645566

2021

Link zum Volltext

Verfügbarkeit prüfen

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.216-227

2017

Link zum Volltext

Verfügbarkeit prüfen

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

Diabetes (New York, N.Y.), 2011-05, Vol.60 (5), p.1561-1565

2011

Link zum Volltext

Verfügbarkeit prüfen

Consensus report: definition and interpretation of remission in type 2 diabetes

Diabetologia, 2021-11, Vol.64 (11), p.2359-2366

2021

Link zum Volltext

Verfügbarkeit prüfen

Unraveling the Science of Incretin Biology

The American journal of medicine, 2009-06, Vol.122 (6), p.S3-S10

Nauck, Michael A., MD, PhD

2009

Link zum Volltext

Verfügbarkeit prüfen

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

The American heart journal, 2013-11, Vol.166 (5), p.823-830.e5

2013

Link zum Volltext

Verfügbarkeit prüfen

Incretin-Based Therapies: Viewpoints on the way to consensus

Diabetes care, 2009-11, Vol.32 (Suppl 2), p.S223-S231

2009

Link zum Volltext

Verfügbarkeit prüfen

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Diabetes, obesity & metabolism, 2020-10, Vol.22 (10), p.1886-1891

2020

Link zum Volltext

Verfügbarkeit prüfen

Another milestone in the evolution of GLP-1-based diabetes therapies

Nature medicine, 2021-06, Vol.27 (6), p.952-953

2021

Link zum Volltext

Verfügbarkeit prüfen

SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?

Endocrinology (Philadelphia), 2020-08, Vol.161 (8), p.1

2020

Link zum Volltext

Verfügbarkeit prüfen

Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review

Scientific reports, 2022-12, Vol.12 (1), p.21069-21069

2022

Link zum Volltext

Verfügbarkeit prüfen

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

Diabetes care, 2013-07, Vol.36 (7), p.2126-2132

Nauck, Michael A

2013

Link zum Volltext

Verfügbarkeit prüfen

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study

Cardiovascular diabetology, 2023-06, Vol.22 (1), p.153-153, Article 153

2023

Link zum Volltext

Verfügbarkeit prüfen

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2022-01, Vol.107 (1), p.1-9

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 444

Suche als RSS-Feed

Aktive Filter

KollektioneBooks on EBSCOhost

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(397)
Mit Volltextzugriff
(400)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(292)
Life Sciences & Biomedicine
(275)
Humans
(266)
Endocrinology & Metabolism
(181)
Male
(144)
Diabetes
(138)
Female
(128)
Middle Aged
(110)
Diabetes Mellitus, Type 2 - Drug Therapy
(105)
Biological And Medical Sciences
(97)
Medical Sciences
(85)
Adult
(84)
Diabetes Mellitus
(79)
Aged
(75)
Glucose
(75)
Type 2 Diabetes
(71)
Insulin
(62)
Hypoglycemic Agents - Therapeutic Use
(60)
Internal Medicine
(60)
Endocrinopathies
(59)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Do GLP-1-Based Therapies Increase Cancer Risk?

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family

Long COVID - metabolic risk factors and novel therapeutic management

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

Consensus report: definition and interpretation of remission in type 2 diabetes

Unraveling the Science of Incretin Biology

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

Incretin-Based Therapies: Viewpoints on the way to consensus

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Another milestone in the evolution of GLP-1-based diabetes therapies

SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?

Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Aktive Filter

Suchergebnisse filtern